Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study
2020 · The Lancet HIV · 87 citations
https://doi.org/10.1016/s2352-3018(20)30240-x
M
Max Lataillade
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
69
Papers
2.0K
Citations
22
h-index
36
i10-index
Max Lataillade is an academic researcher from Incyte (United States). The author has contributed to research in topics: HIV/AIDS drug development and treatment & HIV Research and Treatment & HIV/AIDS Research and Interventions. The author has an h-index of 22, co-authored 59 publications.
ORCID: 0000-0001-6103-8967Papers by this author
worksViral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
2017 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 49 citations
https://doi.org/10.1097/qai.0000000000001602
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
2023 · Infectious Diseases and Therapy · 17 citations
https://doi.org/10.1007/s40121-023-00870-6
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
2021 · Patient · 7 citations
https://doi.org/10.1007/s40271-021-00534-y
Calculated (Model 2a) <i>vs</i>. observed responses for BMS-955176 and BVM vs. clinical results.
2016 · Figshare · 0 citations
https://doi.org/10.1371/journal.ppat.1005990.g012
Antiviral Activity of MIs Toward Gag Polymorphic Viruses
2016 · Figshare · 0 citations
https://doi.org/10.1371/journal.ppat.1005990.t001
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat